Navigation Links
New therapies increase survival rates in post-transplant liver cancer patients
Date:3/25/2010

A recent study found that sirolimus-based immunosuppression following liver transplantation in patients with non-resectable hepatocellular carcinoma (liver cancer) significantly increases survival rates for this patient population. Results of this study appear in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases (AASLD).

According to the NIH, hepatocellular carcinoma (HCC) is a common type of liver cancer, and one of the few cancers in the U.S. in which the number of new cases is expected to rise over the next two decades. Liver transplantation is an important treatment option for selected patients with non-resectable HCC, but the ideal immunosuppression protocol is still a matter of debate. To date, no single protocol has gained widespread acceptance.

Researchers at the University of Alberta led by Dr. Christian Toso set out to define the immunosuppressant regimen associated with the best survival after liver transplantation for HCC. This study was not designed to look at the effect of specific drugs, but at protocols containing specific drugs. Based on data from the Scientific Registry of Transplant Recipients, the researchers evaluated 2491 adult recipients of isolated liver transplantation for HCC and 12167 for non-HCC diagnoses between March 2002 and March 2009. All patients remained on stable maintenance immunosuppression protocols for at least six months post-transplant. The unique outcome variable of the study was patient survival; all deaths were taken into account in the analysis whether they were associated with HCC or not.

In a multivariate analysis, only anti-CD25 antibody induction and sirolimus-based maintenance therapy were associated with improved survivals after transplantation for HCC. The other studied drugs, including calcineurin-inhibitors, did not demonstrate a significant impact. To determine whether the observed effects were due to a direct impact of the drug on tumor or more on liver transplant in general, the research team conducted a similar analysis on non-HCC patients. While anti-CD25 induction was again associated with a trend toward improved survival, sirolimus showed a trend toward lower rates of survival in non-HCC recipients, confirming the specificity of its beneficial impact to cancer patients.

"Of all protocols, sirolimus-based immunosuppression was the only one associated with an improved post-transplantation survival specific to HCC patients, further reinforcing the clinical evidence of its anti-cancer properties," Dr. Toso concluded. "The use of anti-CD25 antibodies demonstrated similar trends to improved survival in both HCC and non-HCC patients. These observations, together with previous reports combining anti-CD25 antibody induction and delayed introduction of CNIs, speak in favor of the use of this drug after liver transplantation in general."

He adds, "Like any potent immunosuppressive drug, sirolimus is linked to a potential for development of numerous side effects. In general however, we believe that these side effects are relatively minor and easy to manage, and that the data revealed by the present study justify a broader use of protocols including sirolimus after liver transplantation for patients with HCC."

In another recent study on hepatocellular carcinoma, researchers from Seoul Veterans Hospital compared hepatic resection (HR) to radiofrequency ablation (RFA) to treat patients with very early-stage HCC, defined as asymptomatic solitary HCC less than 2cm. Very early stage HCC can be an ideal indication for HR because of the low potential risk of microscopic seeding. According to AASLD guidelines, HR is the treatment of choice for patients with very early stage HCC.

Researchers compared HR and percutaneous RFA for the treatment of compensated cirrhotic patients with very early stage HCC using a Markov model to simulate a randomized trial to compare the overall survival of patients treated with HR, RFA or the combined approach of primary RFA followed by HR for cases of initial local failure.

Team leader Dr. Yun Ku Cho explains the rational behind the study. "Usually, RFA is inferior to HR in terms of local recurrence, which is known to be a significant adverse prognostic factor for survival. However, if initial local treatment failure following RFA can be further treated by HR, survival outcomes of patients treated with primary RFA may be improved." He concluded, "The results of this study matched such an expectation, with both study groups achieving nearly identical overall survival rates. Considering that RFA is much less invasive as compared to HR, this study highly suggests that RFA may deserve to be considered as a primary treatment for very early stage HCC."


'/>"/>

Contact: Dawn Peters
medicalnews@wiley.com
781-388-8408
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Study evaluates costs and benefits associated with new colon cancer therapies
2. Intense Cholesterol, Blood Pressure Therapies Dont Help Type 2 Diabetics
3. ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes
4. NIH/NHLBI-funded PACT Group Announces the Renewal of Production Assistance for Cellular Therapies (PACT)
5. ReportsandReports : The Gastrointestinal Market Outlook to 2014: Market Dynamics, Competitive Landscape, Emerging Therapies
6. Notch-blocking drugs kill brain cancer stem cells, yet multiple therapies may be needed
7. MSU researcher linking breast cancer patients with alternative therapies
8. Translational Regenerative Medicine Forum sets stage for accelerating therapies to patients
9. Kids Use of Alternative Therapies Often Mimics Parents
10. Med students say conventional medicine would benefit by integrating alternative therapies
11. China a rising star in regenerative medicine despite world skepticism of stem cell therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... January 16, 2017 , ... Houston dentist, Dr. Behzad ... offering complimentary consultations and financing for orthodontics for a limited time. Complimentary for ... learn about their orthodontic options. Walk-in, late-evening, Saturday, and same-day appointments are available. ...
(Date:1/16/2017)... ... ... well-aware of the following facts at present:, Flu and cold ... effect on keeping this particularly bad strain of the flu away , In ... , These facts are well-known among the team at Woodard! About halfway ...
(Date:1/16/2017)... ... January 16, 2017 , ... San Francisco dentist, Dr. Ben ... in 3-D scanning device which is capable of taking digital impressions of teeth and ... such as CAD CAM restorations , in terms of speed, efficiency and patient ...
(Date:1/15/2017)... ... ... is announcing the release of an updated version of their top selling clipper, the ... wide jaws that will accommodate nails up to 4mm in thickness . Nails like ... reinforced for extra strength when pressing down on dense nails which can be a hindrance ...
(Date:1/15/2017)... , ... January 15, 2017 , ... The Gravity Vault ... in Radnor, Pennsylvania. As construction wraps up on the 14,000+ square foot climbing gym, ... Vaults sixth location, including three in New Jersey and two in New York. With ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... Jan. 16, 2017  Today, Analytics 4 Life (A4L), ... announced its expansion into JLABS @ Toronto ... science incubators. As a resident in the space, A4L ... device development and commercialization expertise. JLABS @ ... innovation center that provides a flexible environment for start-up ...
(Date:1/15/2017)... , January 16, 2017 Le conseil ... à base de collagène pour la régénération de tissus humains, ... poste de directeur général avec effet immédiat. ... Bill est un dirigeant ... occupé plusieurs postes de gestion générale et de direction au ...
(Date:1/13/2017)... Stock-Callers is currently reviewing the following Medical Appliances ... WMGI ), Varian Medical Systems Inc. (NYSE: VAR ... NuVasive Inc. (NASDAQ: NUVA ). These companies belong ... finish on Thursday, January 12 th , 2017, with the ... health care companies in the S&P 500 were down less ...
Breaking Medicine Technology: